Vascular smooth muscle cells (vSMC) are essential to the integrity of blood vessels, and therefore an attractive target of therapeutics aimed at improving vascular function. Smooth muscle cells are one of the few cell types that maintain plasticity and can switch phenotypes from differentiated (contractile) to de-differentiated (synthetic) and vice versa. As small regulatory transcripts, miRNAs act as genetic 'fine tuners' of posttranscriptional events and can act as genetic switches promoting phenotypic switching. The microRNA miR26a targets the BMP signalling effector, smad1. We show that loss of miR26 leads to hemorrhage (a loss of vascular stability) in vivo, suggesting altered vascular differentiation. Reduction in miR26a levels increases smad1 mRNA and phospho-Smad1 (pSmad1) levels. We show that increasing BMP signalling by overexpression of smad1 also leads to hemorrhage and that normalization of Smad1 levels through double knockdown of miR26 and smad1 rescues hemorrhage suggesting a direct relationship between miR26 and smad1 and vascular stability. Using a BMP genetic reporter and pSmad1 staining we show that the effect of miR26 on vascular instability is non-autonomous; BMP signalling is active in embryonic endothelial cells, but not in smooth muscle cells. Nonetheless, increased BMP signalling due to loss of miR26 results in an increase in acta2-expressing smooth muscle cell numbers and promotes a differentiated smooth muscle morphology. Taken together our data suggests that miR26 modulates BMP signalling in endothelial cells and indirectly promotes a differentiated smooth muscle phenotype. Our data also suggests that crosstalk from BMP-responsive endothelium to smooth muscle is important for its differentiation.
Introduction
Vascular smooth muscle cells (VSMCs) provide structural integrity to the vessel wall. Guided control of signalling cascades, including Platelet Derived Growth Factor (PDGF), Notch, and Transforming Growth Factor-β/Bone morphogenic Protein (TGF-β/BMP) , recruit and induce a perivascular niche of cells termed mural cells (comprising of pericytes and immature vSMCs) to create a two-layered vessel wall with an internal endothelial cell lining and a muscle cell covering (Gaengel et al. 2009; Lamont et al. 2010; Liu et al. 2007) . Once the vSMCs surround the vessel they begin depositing extracellular matrix proteins such as laminin, collagen IV and fibulins to support cellular contacts (Rensen et al. 2007 ). vSMCs then take on a mature contractile phenotype that stabilizes the underlying endothelial cells through induction of quiescence, expression of junctional and attachment protein, and expression of contractile proteins to provide myogenic tone (Lamont et al. 2010; David et al. 2008; Owens et al. 1996; Whitesell et al. 2014) .
vSMCs maintain phenotypic plasticity and can undergo a phenotypic switches from a quiescent contractile state to a proliferative synthetic state in response to various cellular stimuli (Rensen et al. 2007; Hendrix et al. 2005) . Contractile vSMC are defined by an elongated, spindle-shaped morphology and low rates of proliferation. The expression of key differentiation markers such as smooth muscle (α)actin (Acta2), smooth muscle β-myosin heavy chain (Myh11), and transgelin (Sm22α) allows vSMCs to perform their contractile function and provide vascular tone. In contrast, rhomboid, immature (synthetic) vSMCs are highly proliferative, produce ECM proteins and have reduced expression of contractile genes (Owens et al. 2004; Mack & Owens 1999; Miano et al. 1994; Lehoux et al. 2006) .
Cumulative studies have demonstrated that BMPs and Smad1 signaling have roles in modulating vSMC plasticity (reviewed by Cai et al. 2012) . Aberrant vSMCs phenotype switching plays a critical role in the pathogenesis of vascular diseases, such as hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), with defective BMP signalling. The diseases affect both endothelial function and vSMC differentiation (Li et al. 1996; El-Bizri et al. 2008; Torihashi et al. 2009; Benjamin et al. 1998; Lan et al. 2007; Roman et al. 2002; Beppu et al. 2000; Mishina et al. 1995) . Murine homozygous null mutants for BMPR-1a (Activin like kinas 3, ALK3) or the type II receptor BMPR-2 (which is mutated in human patients with PAH) (Paul et al. 2005; Orvis et al. 2008 ) and their ligand Bmp4 or downstream co-SMAD4 are embryonic lethal, and present with vascular deformities attributable to a loss of Smad1 mediated signalling (Sirard et al. 1998) . Mutations in ALK1 led to HHT2, a disease characterized by arteriovenous malformations (AVMs) (McDonald et al. 2011) . Deletion of Alk-1 in mice leads to cranial hemorrhages, AVM-like fusion of micro-vessel plexi, dilation of large vessels and reduced coverage of vessels by vSMCs (Park et al. 2006) . In fish, while disruption of Alk1 signalling results in pathological arterial enlargement and maladaptive responses generate AVMs, additional vSMCs defects have not been assessed (Corti et al. 2011) .
As small noncoding RNAs, microRNAs (miRs) are genetic cues that regulate gene expression of key vSMC marker genes to control vSMC dynamics. (Albinsson et al. 2010; Ji et al. 2007; Xie et al. 2011; Zhang 2010) .
A number of miRNAs have been identified as modulators of the vSMC phenotype in vitro and in vivo, including miR-145, miR-21, miR-221, miR-222 and miR-146a (Zeng et al. 2009; Rangrez et al. 2011; Xu et al. 2011; Sarkar et al. 2010; Ali et al. 2015; Sun et al. 2011; Wang et al. 2010; Xin et al. 2009; Cordes et al. 2009 ). (Xin et al. 2009; Cordes et al. 2009; Zeng et al. 2009; Wang et al. 2010; Sarkar et al. 2010; Rangrez et al. 2011; Bai et al. 2011; Sun et al. 2011; Xu et al. 2011; Ali et al. 2015) We previously showed that miR-145 promotes visceral smooth muscle differentiation via controlling cross-talk between visceral epithelial cells and smooth muscle (Zeng et al. 2009; Zeng & Childs 2012) .
In this study we investigated the role of microRNA26a (miR26a) in regulating vSMC dynamics the zebrafish model of vessel stabilization. miR26 has been identified as a potential regulator of vSMC proliferation, migration and differentiation of vSMCs in vitro (Icli et al. 2014; Leeper et al. 2011; Bai et al. 2011; Yang et al. 2017) . miR-26a expression is altered during abdominal aortic aneurysm (AAA) and neointimal lesion formation (Leeper et al. 2011; Yang et al. 2017) , and although primarily categorized as endothelial defects, the pathological progression and compromised vessel structure is attributed to a shift in vSMC phenotypes. However, the significance and cell autonomy of these interactions in an intact animal and in context of developing vSMC are largely unknown. Using a combination of transient knockdown methods to understand the effect of decreasing miR26a levels in vivo, we show that miR26a acts within a BMP responsive pathway to fine tune vascular smooth muscle cell maturation via targeting smad1. However, active BMP signalling was observed within endothelium in vivo, and not in smooth muscle cells. Together the evidence suggests that miR26a has a role in regulating blood vessel stabilization via a non-autonomous mechanism.
Materials and Methods:
Zebrafish Zebrafish (Danio Rerio) embryos were collected and incubated at 28.5 °C in E3 embryo medium and staged in hours post-fertilization (hpf) or days post fertilization (dpf). Endogenous pigmentation was inhibited from 24 hpf by the addition of 0.003% 1-phenyl-2-thiourea (PTU, Sigma-Aldrich) in E3 embryo medium. All animal procedures were approved by the University of Calgary Animal Care Committee. The fluorescent transgenic endothelial mCherry-expressing Tg(kdrl:mcherry) ci5 , GFP-expressing Tg(kdrl:EGFP) la116 and Tg(fli:nEGFP) y7 (Roman et al. 2002 )report endothelial expression, Tg(acta2:GFP) ca7 and Tg(acta2:mCherry) ca8 report smooth muscle expression (Whitesell et al. 2014 ) and BMP-reporter fish Tg(BRE-AAVmlp:eGFP) mw29 [hereafter BRE:eGFP] report active BMP signaling (Collery & Link 2011) .
Morpholino knockdown, CRISPRi and mRNA overexpression
Both MO and mimic were injected into one-to four-cell stage embryos within recommended dosage guidelines (Bill et al. 2009; Schulte-Merker & Stainier 2014) . Injected doses were 1ng/embryo for miR26 MO, Scr. control miR26, and smad1 MO. Morpholinos (MO) were obtained from Gene Tools LLC Corvalis, OR, USA. mir-26a MO blocks the mature microRNA (5-AGCCTATCCTGGATTACTTGAAC-3'), miR26a
Scrambled control has 6bp mismatch (5'-ACCGTATCGTGCATTACTTCAAC-3'), and smad1 MO blocks Smad1 translation (5'-AGGAAAAGAGTGAGGTGACATTCAT-3'). For rescue experiments embryos were first injected with miR26MO and then smad1 MO. To control for non-specific neural cell death that occurs from nonspecific activation of p53 with morpholinos, a standard p53 MO was co-injected with high dose morpholino to establish dosage curve. Hsa miR26a miRIDIAN mimic was obtained from Dharmacon and injected in a dose of 3ng/embryo. For CRISPRi mediated knockdown of miR26a, sgRNA target were designed using CHOPCHOP (Montague et al., 2014) to target the seed sequence of miR26a family members to reduce miR26 processing (miR26a-1, 26a-2, 26a-3, are independent genes located on different chromosomes. miR26b differs by one nucleotide). To generate sgRNA we followed a method established by (Narayanan et al. 2016) . 10 μmol of forward primer and 50 μmol of a universal reverse primer (IDT Oligos, Yale) were annealed and filled in (Montague et al. 2014) , purified (Qiagen PCR purification kit) and in vitro transcribed (T7 mMessage machine, Ambion). Primer sequence information is in supplemental table 1. Zebrafish codon optimized dCas9 plasmid (Rossi et al. 2015) was linearized with XbaI and in vitro transcribed using Ambion Maxi Kit (Life Technologies Inc., Burlington, ON), and RNA purified using an RNeasy Mini Kit (Qiagen).
Zebrafish embryos at the one-cell stage were injected with 200pg of a solution containing 75 ng/μ l of sgRNA with 150 ng/μl of Cas9 mRNA.
For overexpression of smad1, mRNA was in vitro transcribed as described (McReynolds et al. 2007 ; gift from Todd Evans Lab) using mMessage mMachine (Life Technologies Inc., Burlington, ON). 40pg of mRNA was injected per embryo at the 1 cell stage.
Small molecule inhibition
K02288 was used at a dose of 15µM (SML1307, Sigma). DSMO (D8418, Sigma) was used as a vehicle and control. Drug stocks were heated for 20min at 65C and then diluted in E3 embryo medium. Drug or control was applied to the from 52hpf until 4dpf. Embryos were grown at 28.5C in the dark until imaging, and drug changed once.
qPCR analysis
Total RNA from 5-10 zebrafish embryos (or heads) per treatment group was isolated using the RNeasy Mini kit for mRNA or the miRNAs Mini kit for miRNA (Qiagen). For microRNA expression, 100ng of total RNA from each sample were reverse transcribed using the miRCURY LNA™ Universal RT cDNA Synthesis Kit and expression assayed using the miRCURY LNA™ Universal RT microRNA PCR System (Qiagen). The ΔΔCt method was used to calculate the normalized relative expression level of a target gene from triplicate measurements. Experiments were repeated independently at least three times. Primer sequences are listed in Table S1 , expression levels normalized to that of miR-103a-3p or miR122 for miRNA expression.
In situ hybridization and Immunostaining
Embryos were fixed in 4% paraformaldehyde in PBS with 0.1% Tween-20 at 4 °C overnight, followed by 100% methanol at −20 °C. For wholemount in situ hybridization embryos staining Digoxigenin (DIG)labeled antisense RNA probes. Probes for smad1 (construct describe by McReynolds et al. 2007 ) sm22a, acta2, myh11a were synthesized from PCR fragments amplified from embryonic zebrafish cDNA using the primers listed in supplementary table 1. Probes were synthesized by using SP6 or T7 RNA polymerase (Roche). miR26a double-DIG-labeled LNA probe was obtained from Exiqon. Phospho-SMAD1/5/9 (pSMAD1/5/9) was detected with Rabbit anti-Phospho-Smad1
(Ser463/465)/Smad5(Ser463/465)/Smad9(Ser426/428) (1:400; Cell Signaling Technology) using an antigen retrieval protocol, GFP was detected with mouse anti-GFP antibody, JL8 (1:500, Clontech) and detected with Alexafluor 647 or 488 secondary antibodies (1:500; Invitrogen Molecular Probes).
Imaging and statistical analysis:
For imaging, embryos were immobilized in 0.004% (g/mol) Tricaine (Sigma) and mounted in 0.8% low melt agarose on glass bottom dishes (MatTek, Ashland, MA). Confocal images were collected on a Zeiss LSM 700 inverted microscope. Image stacks were processed in Zen Blue and are presented as maximal intensity projections. For cell counts images were converted to 16-bit images using ImageJ and threshold adjusted to allow counting of cells over a region of the VA from the anterior bulbous arteriosus to the most anterior PAA.
Data are expressed as mean ±SD. Two treatment groups were compared using Student's t-test. Three or more treatment groups were compared by one-way ANOVA followed by post hoc analysis adjusted with a least significant-difference correction for multiple comparisons using GraphPad Prism version 7.00(La Jolla California USA).
Results:
miR26a is expressed in vicinity of developing blood vessels miR26a targets smad1 and thereby directly regulates BMP signalling (model; Figure 1A ). To observe the spatial gene expression pattern of miR26a in developing embryos we used in situ hybridization. At 48hpf, miR26a has a ubiquitous expression pattern (Figure 1 B-B' ), however by 4 dpf the expression pattern becomes more localized in the ventral head of the embryo, with strong expression in the pharyngeal region, bulbous arteriosus and ventral aorta ( Figure 1C ). We observe that miR26a is expressed in and around the blood vessel endothelium (compare to kdrl:GFP transgenic signal; Figure 1C ', inset C'') and may therefore play a role modulating BMP signalling in blood vessels.
BMP signalling is highly active in aorta endothelium of wild type embryos
We next tested where BMP signalling was active using an in vivo reporter of Smad1/5 activity.
Tg(BRE:eGFP] transgenic fish encode eGFP driven by an upstream Bmp Response Element (BRE) that contains multiple short Smad-binding sites from the id1 promoter, a major transcriptional target activated by canonical Bmp/Smad1 signaling (Collery & Link 2011; Laux et al. 2011) . We crossed Tg(BRE:eGFP] to Tg(kdrl:mcherry) or Tg(acta2:mCherry) to localize active BMP signalling in endothelial and vSMCs respectively (Figure 1 D and G) . vSMC cells first differentiate and begin to express the mature marker acta2 between 3 and 4dpf (Whitesell et al. 2014; Georgijevic et al. 2007) . Surprisingly, although data suggests, that in early development, the endothelium, but not vSMCs respond to BMP signalling as visualized by two methods of detection.
Knockdown of mir26a leads to upregulation of smad1 and loss of vascular stability
The highly conserved miR-26 family constitutes miR-26a-1, miR-26a-2, and miR-26b (Bai et al. 2011 ) as identified by their seed sequences and accessory sequence. In zebrafish, and humans, miR-26a-1, miR-26a-2 and miR26a-3 have the same mature sequence, and only differ from the mature miR-26b sequence by two nucleotides (Icli et al. 2014; Griffiths-Jones et al. 2008) . To investigate the role of miR26a in vascular development in vivo, we knocked down miR26a using an antisense morpholino that targeted the mature miRNA seed sequence of all three miR26a isoforms. A 6bp mismatch morpholino was used as a control. 1ng doses of morpholino were used, as suggested by current guidelines (Bill et al. 2009; Bedell et al. 2011) . In parallel, we designed a second genetic knockdown approach using CRISPR interference (CRISPRi) (Long et al. 2015) , to target the pri-miRNA hairpin structure using the complementary sequence to the mature miRNA (Figure 2 A) . RT-qPCR shows a 22% reduction in miR26
following miR26a MO knockdown and 24% reduction with miR26a CRISPRi (Figure 2 B and C and) confirming that both knockdown methods result in decreased miR26a expression. The knockdown is dose-responsive; higher morpholino doses lead to a 1.8-fold reduction in miR26a expression (Supplemental Figure 3 A and B ). In support of smad1 being a target of miR26a in vivo, miR26a
knockdown resulted in increased smad1 mRNA expression in 2dpf and 4dpf injected embryos as compared to controls by in situ hybridization ( Figure 2D ). Upregulation of smad1 was more prominent in the head of miR26a morphants and CRISPRi knockdown embryos, with a localization similar to where miR26a is expressed most strongly ( Figure 1B-C) . At 4dpf in both morphants and CRISPRi fish, smad1
expression is upregulated in the pharyngeal region, with staining in the ventral aorta, aortic arches and bulbous arteriosus.
In a complementary approach we injected a miR26 mimic to overexpress miR26a (Supplemental Figure   2 ) and observed a marked increase in miR26a expression by qPCR and in situ hybridization (Supplemental Figure 2A , C and D). Overexpression of miR26a resulted in mildly dorsalized embryos by 48hpf with heart edema, dorsal axis defects and poor circulation (Supplemental Figure 2D ), suggesting overexpression of miR26 disrupts pathways such as BMP that pattern early embryonic axes.
Increased levels of smad1 lead to vascular stability defects.
At 2dpf, miR26a morphants have an average 13±2% hemorrhage (Figure 3 B and D) and CRISPRi embryos have an average 15±1% hemorrhage (Figure 3 C and D) . The phenotype is dose-dependent as higher doses of morpholino lead to an increase in hemorrhage to 40% (Supplemental Figure 3 C and D). As smad1 is a known target of miR26a, but upregulation of smad1 has not been previously connected to vascular stability defects, we overexpressed smad1 by injection of mRNA into single cell stage embryos.
Injection of smad1 mRNA alone resulted in significantly higher hemorrhage rate of 22% in injected embryos as compared to uninjected controls ( Figure 3F and I). Next, as miR26a knockdown leads to increased smad1 levels, we predicted that reduction in smad1 would rescue hemorrhage in miR26 knockdown embryos. We used a double morpholino knockdown strategy using co-injection of a validated smad1 MO with the miR26a morpholino, both at 1ng/embryo. Double knockdown reduced hemorrhage rates to below 5% (Figure 3H , top embryo and Figure 3I ). smad1 MO alone does not result in hemorrhage;
however it did result in a range of phenotypes associated with smad1 knockdown including dorsal-ventral axis defects and hydrocephalus as previously reported (McReynolds et al. 2007) . smad1 knockdown led to 80% of embryos with a mild (V1) ventralized defect and 15% with a more severe (V2) ( Figure 3G and I). Both defects were reduced in double knockdown embryos (Figure 3 G and H, bottom embryos) . Thus reducing miR26a levels by either MO or CRISPRi knockdown in vivo leads to an increase in smad1 levels.
Increasing smad1 leads to a vascular stability defects, while reducing Smad1 levels in miR26a morphants normalizes the phenotype.
Loss of miR26a leads to increased phosphorylated Smad1 in endothelium
We next tested whether the increased expression of smad1 mRNA in miR26a knockdown embryos was also indicative of enhanced Smad1 activation by phosphorylation. Wildtype immunostaining showed pSmad1/5/9 is highest within the endothelium and not vSMCs (Supplemental Figure 1 B-B' ). Using 
Loss of miR26a leads to increased numbers of acta2-positive vSMCs and a differentiated morphology
As both miR26a and smad1 are implicated in controlling vSMC differentiation, we investigated if there was a functional consequence of the increased endothelial BMP signalling on vSMCs. We assayed the expression of a key set of marker genes that are highly expressed in differentiated vSMCs. Using in situ hybridization, we found that miR26 morphant embryos have increased expression of acta2 and myh11a, especially in the pharyngeal region where vSMCs first develop ( Supplementary Figure 5 A-B and C-D). This is also a similar location to that of increased smad1 staining ( Figure 2D ). Conversely by 4dpf miR26 mimic injected embryos had reduction in acta2 and sm22 expression ( Supplementary Figure 5 E-G and H-I).
Taking advantage of live reporters, we quantitated vascular smooth muscle of the ventral aorta and pharyngeal arch arteries in miR26 morphants ( Figure 5A ). This assay allows us to make a number of key observations. First, the BRE:GFP signal appears to be enhanced in miR26a morphants ( Figure 5 A' , B' and C). Although this observation is not significant it correlates with increased pSmad1 staining (Figure 4) .
Second, the number of acta2:GFP positive cells along the ventral aorta and pharyngeal arch arteries (PAA) are increased in miR26 knockdown embryos (33.8±1.6 vs 47.22±2.2, Figure 5 A', B' and D) . Third, the increase in acta2 positive cell number, is accompanied by a qualitative change in cell morphology of miR26a knockdown embryos. In control embryos, 25% of total acta2 positive cells have a rounded, punctate morphology, and 'sit' high on the vessel wall. The remaining cells having a more mature spindle, flattened morphology. In miR26 morphants, 13% appear rounded while the majority, 86%, are spindle like cells. This data suggests that loss of miR26a results in increased vSMC coverage along blood vessels that vSMCs, and a shift to a more differentiated phenotype.
Inhibition of the BMP pathway reverses the effects of miR26a knockdown
Given that pSmad1 levels are increased within the endothelium of miR26a knockdown embryos and that these embryos also have an increased number of vSMC, we investigated whether blocking BMP signalling reverses the effect of loss of miR26a on vSMC number and differentiation. We used a pharmacological approach to reduce receptor phosphorylation of Smad1. K02288 is a selective and potent inhibitor of the BMP type I receptor activin like kinase 1 (Alk1) and Alk2. To select appropriate timepoints, the endothelium of the major blood vessels are patterned by 48hpf (Isogai et al. 2001) , while vSMC coverage of the ventral aorta and PAA which begins from 52hpf (Whitesell et al. 2014) . Therefore, Tg(acta2:eGFP;kdrl:mCherry) embryos were treated with 15µM d K02288 from 52hpf to 4dpf. Treatment at this later stage also avoids gastrulation defects and allowed us to assay the effects of BMP inhibition during a time when vSMCs first associate with blood vessels.
In wildtype embryos treatment with K02288 led to a 62% reduction in the total average number acta2:eGFP positive cells compared to vehicle control alone (Figure 7 A', D' and G. 29+1 to 11+3). In miR26 knockdown embryos (Figure 7 B'-C') the effects of K02288 were blunted and acta2-positive cell numbers were maintained at comparable levels to wildtype controls. miR26a morphants had a minimal 17% reduction (35+5 to 29+5) and miR26a CRISPRi embryos had a 12% reduction in numbers from 39+1 to 34+3 (Figure 7 E'-F' and G) . This suggests that loss of miR26a, and the subsequent increase in Smad1 may compensate for reduced receptor function and provide enough signal to maintain vSMC coverage.
Alongside the reduction in vSMC number, we also observed an average 50% reduction in the length of ventral aorta length in K02288 treated wildtype embryos at 4dpf, from an average 159µm to 77µm (Figure 7 A, D and H) . This reduction was not seen in miR26a morphants treated with K02288, which maintain ventral aorta length. miR26a CRISPRi embryos had a small, 20% decrease in length when treated with K02288 (Figure 7 B-C and E-F). Of note there was no statistical difference in ventral aorta length between mir26a knockdown and control embryos, which supports our finding that EC cell number is not affected. Taken together, our data indicates blocking BMP signalling effectively reduced vSMC coverage and affects endothelial development in the ventral aorta. miR26a knockdown animals have minimal changes in vSMC coverage in response to BMP inhibition.
Discussion
Compromised structural vascular integrity, vessel weakening and rupture (hemorrhage) can result from aberrant BMP signalling (Dzau et al. 2002; Milewicz et al. 2010; Nebbioso et al. 2012) . Hemorrhage ultimately results from weak endothelial junctions, however defects in mural cell coverage (attachment and ECM secretion) are implicated in the pathological progression of vascular diseases. We show that the underlying endothelium of the ventral aorta in zebrafish has activated pSmad1 at 4 dpf, but that pSmad1 is not detectable in mural cells. At a stage when mature vSMC are normally present, embryos with loss of miR26a have upregulation of pSmad1, increased vSMC coverage and a change in vSMC morphology, with no observable changes in the number, or morphology of the pSmad1-expressing endothelial cells. We show that inhibition of BMP signalling reduces both vSMC coverage and the length of the ventral aorta while dual miR26 knockdown and BMP receptor inhibition leads to a rescue such that animals maintain normal vSMC number, length of the ventral aorta, and vSMC coverage. We therefore suggest that miR26a modulates BMP signalling in endothelial cells to control vSMC differentiation via yet unidentified paracrine mechanism' paracrine mechanism, and that miR26a functions to fine tune endothelial signals to the vSMCs (Figure 8 ).
Studies in cultured vSMC have suggested that miR26a controls Smad1-mediated BMP signalling within SMCs to modulate their phenotype (Albinsson et al. 2010 ). However, these in vitro studies do not address whether the levels of pathway activation in vitro are relevant to tissues in vivo. Additionally, data collected from in vitro culture systems does not address the role of cell to cell communication (autonomous and non-autonomous signalling) that is critical in vivo (Gaengel et al. 2009; Owens et al. 2004 ). We therefore sought to use a live model of vascular development with intact tissue and cellular contexts. Using a BMP-reporter transgenic fish, we found that during normal development, and under physiological conditions, vSMC directly contact BRE-positive and pSmad1 positive endothelial cells but have undetectable BRE or pSmad1 signal in themselves. This important finding suggests that endothelial cells are key for responding to physiological BMP signals.
Treatment with K02288, a potent ALK1/2 inhibitor, significantly reduced both acta2-positive vSMC coverage and reduced the length of the ventral aorta. miR26 knockdown embryos showed minimal reductions in both vSMC number or VA length, which suggest that the enhanced Smad1 activation in these embryos compensates for the receptor inhibition. ALK1, ALK2 and ALK3 are expressed in both endothelial and vSMCs (Benjamin et al. 1998; Lan et al. 2007; Roman et al. 2002; Beppu et al. 2000; Mishina et al. 1995) , however our data suggests that although vSMC in vitro have the potential for autonomous BMP signalling, in vivo, and under physiological conditions endothelial Smad1 activation contributes to non-autonomous vSMC coverage. In zebrafish Alk1 is highly expressed in the endothelium by 36hpf (Laux et al. 2011) . Violet beauregarde (vbg ft09e ) alk1 loss of function zebrafish mutants develop striking cranial vessel abnormalities by 2dpf due to increased endothelial cell (EC) proliferation (Roman et al. 2002) . vbg ft09e are also unable to limit the diameter of arteries carrying increasing flow from the heart (Corti et al. 2011) . Based on our data involving indirect control by endothelial signalling, we would predict there is a defect in vSMC recruitment when Smad1 signalling downstream of Alk1 is disrupted in these mutants, although this remains to be tested.
Our data suggests that the normal function of miR26 is to reduce Smad1 protein activation within the endothelium, and indirectly inhibit vSMC differentiation in early development. Endothelial and mural cells signal through several paracrine pathways to stabilize vessels including the PGFRβ, angiopoietin, TGFβ, and notch pathways to modulate cell-to-cell communication (Mack 2011; Winkler et al. 2011) .In one of the most important pathways for mural cell recruitment, endothelial cells release PDGF-BB ligands that acts on the mural cell receptor PDGFR-β to initially recruit vSMCs to blood vessels (Benjamin et al. 1998; Lindahl et al. 1997) . There is evidence that miR26 is modulated by PDGF-BB signalling (Yang et al. 2017 ). Yang et al, 2017 , recently showed that neointimal hyperplasia results in elevated levels of PDGF-BB and is associated with upregulation of miR26 and the accumulation of vSMC at sites of injury, indicative of increased proliferation. Furthermore, treatment of primary mouse aortic vSMCs with miR26a mimic drives cells to a synthetic vSMC state (Yang et al. 2017) . Currently the link between increased PDGF-BB and miR26 is unknown, however because PDGF-BB is primarily released by endothelial cells, it should be explored whether it is activated downstream of Smad1 activation.
While we found increased differentiation of vSMCs at the later stage 4 dpf timepoint, at 48hpf loss of miR26 results in hemorrhage. The 2dpf to 4dpf window is a common window for vascular instability phenotypes to emerge in zebrafish (Zheng et al. 2010; Liu et al. 2007; Montero-Balaguer et al. 2009; High et al. 2008) . BMP signalling is initiated in endothelium at this timepoint and perturbations can affect endothelial cell junction development (Winkler et al. 2011) . We have previously shown mural cells present around vessels by 2dpf, although they are mesenchymal and immature (Liu et al. 2007 ). These cells express PDGFRβ but have no expression of mature vSMC markers (Ando et al. 2016 ) , suggesting the 48hpf timepoint represents a critical window for vascular mural cell attachment to endothelium and differentiation to a mature phenotype. Paracrine signals from endothelium regulated downstream of miR26 could affect mural cell differentiation, leading to vascular instability.
As critical modulators of vascular cell function and with roles in cell differentiation, contraction, migration, proliferation and apoptosis, microRNAs are attractive targets of therapeutic treatments aimed at modulating the vSMC phenotypic switch. Specific to TGF-β/BMP signalling, the mir-145/143 family has direct involvement in SMC differentiation by repressing the Klf4 to induce a contractile morphology and reduced rates of proliferation (Cordes et al., 2009) . miR-21 controls vSMC differentiation through crosstalk with miR-143/-145 (Sarkar et al., 2010) and by mediating TGF-β/BMP induction to promote miR-21 cleavage to its mature form and a more contractile phenotype ( Figure 5 ). miR26 is unique in this group in that it represses smooth muscle differentiation to mature states, likely via a paracrine signalling from endothelial cells. As drug delivery to the endothelium is relatively straightforward, modulation of miR26a might be therapeutically useful for post-transcriptional control of key genes involved in vSMC phenotypic switching. 
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